HOUSTON, Jan. 14, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biotechnology company specializing in the
development of novel treatments for brain tumors, today announced
it has signed a contract with NCK A/S for the large scale
production of Berubicin, its lead drug candidate for the treatment
of glioma brain tumors.
NCK A/S is a GMP manufacturer of complex drugs located in Farum,
Denmark, and the previous producer
of Berubicin for Reata Pharmaceuticals. Production of large scale
Berubicin is set to commence in January and will ensure drug
availability through the end of Phase II clinical trials for
glioblastoma.
"We are extremely excited to have entered into a contract with
NCK A/S. We believe working with an experienced company in the
production of this class of anthracyclines is paramount given the
complex chemistry and difficulty to produce very high purity for
human use," stated John Climaco, CEO
of CNS Pharmaceuticals. "We are confident in NCK A/S' ability to
succeed in the large scale production of our lead candidate due to
its extensive experience in Berubicin synthesis for previous
clinical trials. This contract represents a key stride in the
development of Berubicin and secures drug availability as we look
forward not only to initiate but also expand Phase II clinical
trials later this year."
About Berubicin
Berubicin is an anthracycline, a class
of anticancer agents that are among the most powerful chemotherapy
drugs and effective against more types of cancer than any other
class of chemotherapeutic agents. Anthracyclines are designed
to utilize natural processes to induce deoxyribonucleic acid (DNA)
damage in targeted cancer cells by interfering with the action of
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin was developed at the MD Anderson Cancer Center
(MDACC), which is the top ranked cancer center in the US, and
largest cancer research and treatment facility in the world.
Berubicin treatment of brain cancer patients appeared to
demonstrate positive responses that include one durable complete
response in a Phase 1 human clinical trial conducted by
Reata.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a biotechnology company specializing in the
development of novel treatments for primary and metastatic brain
and central nervous system tumors. Its lead candidate
Berubicin is proposed for the treatment of glioblastoma, a type of
brain cancer currently considered incurable, as well as for
pancreatic and ovarian cancers, and lymphomas. The Company
entered into an intellectual property (IP) agreement with Houston
Pharmaceuticals, Inc. and a Purchase Agreement with Reata.
For more information, visit www.cnspharma.com.
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of the Company to prepare
its IND and to commence its upcoming potential Phase II study.
These statements relate to future events, future expectations,
plans and prospects. Although CNS believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. CNS has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Risk Factors" in the Form S-1 we filed
with the SEC on October 7, 2019. Any
forward-looking statements contained in this release speak only as
of its date. CNS undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-contract-with-international-gmp-manufacturer-for-production-of-berubicin-300986285.html
SOURCE CNS Pharmaceuticals, Inc.